About us


Scroll To Explore


We are committed to improve patients’ life by delivering innovative cancer immunotherapies and treatments for neurologic disorders and rare diseases.


We aim at making an impactful difference for patients suffering from cancer by discovering first-in-class and best-in-class treatments that tackle GPCR -mediated immunosuppression.

Leveraging our expertise, innovative approach and proprietary platform, we develop a unique pipeline in immune-oncology and progress our most advanced programs towards the clinic.

Over the last decade, the company has also created a proprietary pipeline of GPCR-based programs in neurology and rare diseases. Domain is securing its development by establishing early partnerships.

Business model

Domain Therapeutics is creating value for its shareholders by developing in the clinic its proprietary portfolio of programs in immune-oncology and by creating early partnerships on its neurology and rare disease assets.


About us